Literature DB >> 8039240

Anticryptococcal activity of macrophages: role of mouse strain, C5, contact, phagocytosis, and L-arginine.

E Brummer1, D A Stevens.   

Abstract

The antifungal activity of nonactivated resident murine peritoneal macrophages for Cryptococcus neoformans was studied. Macrophages from five of six mouse strains tested had significant (40 to 80%) fungistatic activity, depending on the inoculum size, in a 24-hr coculture system. Macrophages from two outbred (SW and ICR) and three inbred (BALB/c, C57Bl/6, and DBA/2J) strains were fungistatic. Only macrophages from outbred CD-1 mice lacked fungistatic activity. Heat-inactivated and C5-deficient sera did not support phagocytosis or fungistasis by resident BALB/c or DBA/2 macrophages. Fungistasis correlated with contact, complement, and phagocytosis. Macrophages were studied in a Lab-Tek chamber slide system where noningested cells were washed away. Fungistasis in this system was similar to that found with a microtest plate coculture method where a smaller inoculum was cultured continuously with macrophages. After ingestion of yeast cells, CD-1 macrophages could be activated for fungistasis (70%) with interferon-gamma plus lipopolysaccharide. Activated BALB/c macrophages had increased fungistasis but were not fungicidal. NG-Monomethyl-L-arginine (200 microM), which inhibited the fungistatic activity of activated CD-1 macrophages, did not inhibit inherent fungistatic activity of BALB/c macrophages. The fungistatic mechanism of BALB/c macrophages resembled that reported for resident human macrophages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039240     DOI: 10.1006/cimm.1994.1200

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages.

Authors:  J N Steenbergen; H A Shuman; A Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells.

Authors:  T Zhang; K Kawakami; M H Qureshi; H Okamura; M Kurimoto; A Saito
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

3.  Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12.

Authors:  K Kawakami; M Tohyama; X Qifeng; A Saito
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

4.  Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum.

Authors:  Judith N Steenbergen; Joshua D Nosanchuk; Stephanie D Malliaris; Arturo Casadevall
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

5.  Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice.

Authors:  J K Byron; K V Clemons; J H McCusker; R W Davis; D A Stevens
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

6.  Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide.

Authors:  M Tohyama; K Kawakami; M Futenma; A Saito
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

7.  Automated analysis of cryptococcal macrophage parasitism using GFP-tagged cryptococci.

Authors:  Kerstin Voelz; Simon A Johnston; Julian C Rutherford; Robin C May
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

8.  Genetic control of susceptibility to infection with Candida albicans in mice.

Authors:  Irena Radovanovic; Alaka Mullick; Philippe Gros
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

9.  Protective immunity against cryptococcus neoformans infection.

Authors:  Joel Schop
Journal:  Mcgill J Med       Date:  2007-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.